UPDATE: Teva's (TEVA) '302 Capaxone Patent Invalidated by U.S. Patent Office
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - September 1, 2016 2:51 PM EDT)
Teva Pharma (NYSE: TEVA) lost a third court ruling against Mylan (NASDAQ: MYL) related to Teva's drug Copaxone. Today's decision by the U.S. Patent and Trademark Office stated that claims 1-12 of the ’302 patent are held unpatentable. Previously two other patents were invalidated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) and Flowers Baking Reach Settlement in Class Action Lawsuit
- PPG Industries (PPG) Announces Restructuring Plan, Targeting $125M in Yearly Savings
- VirnetX Holding (VHC) Disappointed on Federal Circuit's Decisions; Positive on Dissenter
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!